Testing MLC901 with standard care in mild to moderate ischemic stroke
Tests MLC901 plus standard care against standard care alone in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
Key facts
- Where
- Ho Chi Minh City, VietnamSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07828210, who can take part
Where in Vietnam
- Traditional Medicine InstituteHo Chi Minh City, VietnamTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- EVD Pharmacy and Medical Company Limited
- Trial code
- NCT07828210
- Record updated
- 20 October 2026
- Original description
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard treatment or standard treatment alone for 12 weeks.Read full original descriptionShow less
A Randomized, Controlled Study Evaluating the Efficacy and Safety of MLC901 (NeuroAiD™ II) in Patients With Mild to Moderate Ischemic Stroke.
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard treatment or standard treatment alone for 12 weeks.
Inclusion: Aged 18 to 80 years, inclusive; Diagnosed with ischemic stroke, with brain imaging findings consistent with the diagnosis, and enrolled 2-10 days after stroke onset; Baseline National Institutes of Health Stroke Scale (NIHSS) score of 8-15 at the time of screening; Clinically stable at the time of enrollment; Considered by the treating physician to be a suitable candidate for active rehabilitation; Able to comply with the requirements of the study protocol and has provided written informed consent to participate in the study, either personally or through a legally authorized representative, as applicable, before any study-specific procedures are performed.
Exclusion: Use of Cerebrolysin, piracetam, erythropoietin, edaravone, or vinpocetine within 30 days prior to enrollment; Participation in another investigational drug or medical device trial within 30 days prior to enrollment; Pregnancy or breastfeeding. Women of childbearing potential are eligible only if they commit to complete abstinence from sexual intercourse or use effective contraception (excluding systemic hormonal contraceptives). Participants receiving hormone replacement therapy are not eligible (this applies to premenopausal, postmenopausal, or surgically sterilized women); Other neurological or psychiatric disorders that may interfere with study assessments, including:; Hemorrhagic stroke; Evidence of other significant non-ischemic brain lesions that may affect long-term functional outcomes or disability; Evidence of progressive medical conditions that may interfere with study assessments or follow-up (e.g., cancer, kidney failure, liver cirrhosis, severe dementia, or psychiatric disorders); Any medical, psychiatric, or cognitive condition that, in the investigator's opinion, may place the participant at risk during study participation, interfere with the conduct of study procedures, compromise study follow- up, or confound the study results; Clinically unstable condition within 24 hours after thrombolysis (intravenous/endovascular) or thrombectomy; History of food allergy or hypersensitivity to any component of MLC901; Contraindication to any study procedure; Current use of finished medicinal products or herbal medicinal products containing ingredients that overlap with any component of MLC901.